AstraZeneca (NYSE:AZN) Shares Gap Up – Should You Buy?

AstraZeneca Plc (NYSE:AZN) gapped up before the market opened on Friday. The stock had previously closed at $174.40, but opened at $183.59. AstraZeneca shares last traded at $185.9280, with a volume of 935,803 shares.

Key Headlines Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Core EPS was $2.79 versus consensus estimates near $2.59–$2.60, while revenue reached approximately $16.2 billion, ahead of the roughly $16.0 billion forecast and up about 7% year over year. Net profit rose to $3.12 billion from $2.535 billion. AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth
• Positive Sentiment: Oncology sales were the primary growth engine. Cancer-drug revenue increased 17%, helping offset generic pressure on mature medicines, including the impact from Farxiga competition. The performance reinforces AstraZeneca’s strategy of shifting its portfolio toward innovative, higher-growth therapies. AstraZeneca Q3 profit beats estimates as cancer drug sales drive growth
• Positive Sentiment: Management reaffirmed fiscal 2026 guidance. The company continues to target mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. AstraZeneca also outlined a goal of $1.5 billion in annual savings, which could support margins and earnings. AstraZeneca targets $1.5 billion in annual savings
• Positive Sentiment: Pipeline progress added to the favorable reaction. AstraZeneca reported 12 positive Phase 3 readouts, improving confidence in future product launches and the company’s ability to replenish revenue as older drugs face patent and generic pressures. AstraZeneca Q3 Profit Rises; Pipeline Delivers 12 Positive Phase 3 Readouts
• Neutral Sentiment: Analyst views remained mixed: Guggenheim maintained a Buy rating, while Deutsche Bank kept a Hold rating. Erste Group Bank reportedly lowered its fiscal 2026 EPS estimate, indicating that some concerns about execution, competition and the drug portfolio remain.
• Negative Sentiment: Generic erosion on mature medicines remains a headwind, particularly as Farxiga faces increased competition. The company’s current ratio and quick ratio below 1 also underscore relatively limited short-term balance-sheet liquidity, although the earnings release was the dominant market catalyst.

Analyst Upgrades and Downgrades

Several analysts have commented on AZN shares. CICC Research started coverage on AstraZeneca in a research note on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective for the company. Nordea Equity Research upgraded AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. HSBC cut AstraZeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Royal Bank Of Canada started coverage on AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating for the company. Finally, Zacks Research upgraded shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average price target of $206.67.

AstraZeneca Stock Up 7.1%

The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $289.72 billion, a PE ratio of 27.91, a PEG ratio of 1.31 and a beta of 0.27. The firm’s fifty day moving average is $164.05 and its 200-day moving average is $180.22.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Saturday, October 31st. The company reported $2.79 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The company had revenue of $16.21 billion for the quarter, compared to analyst estimates of $16 billion. During the same quarter in the previous year, the company earned $2.38 EPS. The firm’s revenue for the quarter was up 6.5% compared to the same quarter last year. On average, equities research analysts predict that AstraZeneca Plc will post 10.21 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Amundi grew its stake in shares of AstraZeneca by 146,574.4% during the 1st quarter. Amundi now owns 15,386,149 shares of the company’s stock worth $3,034,456,000 after purchasing an additional 15,375,659 shares during the period. Janus Henderson Group PLC lifted its stake in shares of AstraZeneca by 889.9% in the first quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock valued at $2,319,947,000 after purchasing an additional 10,742,268 shares during the period. Rathbones Group PLC lifted its stake in shares of AstraZeneca by 106,772.0% in the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after purchasing an additional 8,047,406 shares during the period. Royal Bank of Canada boosted its holdings in AstraZeneca by 208.6% during the first quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after buying an additional 7,021,126 shares in the last quarter. Finally, Swiss National Bank purchased a new position in AstraZeneca in the first quarter valued at about $1,202,714,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.